Table 2. Main results of pooled odds ratios (ORs) with confidence interval (CI) in the meta-analysis.
| Sub-group analysis | No. ofdatasets | No. ofcases/controls | G Allele | Dominant Model | Recessive Model | ||||||
| OR (95% CI) | P(Z) | P(Q) | OR (95% CI) | P(Z) | P(Q) | OR (95% CI) | P(Z) | P(Q) | |||
| Overall | 34 | 15368/23959 | 1.03 (0.98–1.09) | 0.25 | 0.05 | 1.03 (0.97–1.10) | 0.33 | 0.06 | 1.02 (0.89–1.17) | 0.79 | 0.25 |
| Cancer type | |||||||||||
| Colorectal cancer (Overall) | 26 | 13465/20430 | 1.03 (0.96–1.09) | 0.25 | 0.008 | 1.03 (0.96–1.12) | 0.39 | 0.01 | 0.99 (0.85–1.15) | 0.86 | 0.23 |
| Colorectal cancer (Caucasians ) | 17 | 11396/17014 | 0.98 (0.91–1.05) | 0.56 | 0.05 | 0.98 (0.91–1.06) | 0.68 | 0.11 | 0.93 (0.91–1.06) | 0.45 | 0.12 |
| Colorectal cancer (Asians) | 7 | 1754/3007 | 1.17 (1.00–1.36) | 0.06 | 0.14 | 1.19 (0.98–1.45) | 0.08 | 0.08 | 1.21 (0.84–1.77) | 0.31 | 0.75 |
| Gastric cancer | 3 | 806/1029 | 1.06 (0.90–1.25) | 0.50 | 0.58 | 1.04 (0.86–1.25) | 0.72 | 0.42 | 1.30 (0.81–2.07) | 0.27 | 0.73 |
| Esophagus cancer | 2 | 483/739 | 1.10 (0.89–1.37) | 0.38 | 0.93 | 1.15 (0.89–1.48) | 0.29 | 0.90 | 0.97 (0.48–1.93) | 0.92 | 0.52 |
| Pancreatic cancer | 2 | 258/1120 | 1.08 (0.82–1.42) | 0.60 | 0.75 | 1.01 (0.73–1.40) | 0.95 | 0.81 | 2.80 (0.40–19.62) | 0.30 | 0.10 |
| Hepatocellular carcinoma | 1 | 356/641 | 1.01 (0.73–1.39) | 0.97 | NA | 0.96 (0.68–1.37) | 0.83 | NA | 1.81 (0.52–6.30) | 0.35 | NA |
| Ethnicity | |||||||||||
| Caucasian | 21 | 12520/18288 | 1.00 (0.94–1.05) | 0.88 | 0.10 | 0.99 (0.93–1.06) | 0.87 | 0.16 | 0.96 (0.82–1.13) | 0.62 | 0.18 |
| East Asian | 11 | 2533/5262 | 1.13 (1.02–1.25) | 0.02 | 0.39 | 1.13 (0.99–1.29) | 0.06 | 0.22 | 1.31 (0.96–1.79) | 0.09 | 0.72 |
| Other | 2 | 315/409 | 1.18 (0.92–1.52) | 0.20 | 0.37 | 1.18 (0.87–1.60) | 0.30 | 0.39 | 1.53 (0.76–3.05) | 0.23 | 0.72 |
| Sample size | |||||||||||
| <500 | 27 | 5854/9773 | 1.07 (1.00–1.14) | 0.05 | 0.34 | 1.07 (0.99–1.16) | 0.08 | 0.34 | 1.14 (0.95–1.38) | 0.17 | 0.87 |
| ≥500 | 7 | 9514/14186 | 0.99 (0.92–1.08) | 0.90 | 0.02 | 0.99 (0.90–1.09) | 0.84 | 0.03 | 0.95 (0.73–1.25) | 0.74 | 0.008 |
| Source of control | |||||||||||
| Population | 23 | 13089/19824 | 1.01 (0.95–1.07) | 0.78 | 0.03 | 1.01 (0.94–1.08) | 0.83 | 0.04 | 0.98 (0.85–1.14) | 0.83 | 0.24 |
| Hospital | 11 | 2279/4135 | 1.13 (1.02–1.25) | 0.02 | 0.77 | 1.14 (1.01–1.28) | 0.03 | 0.73 | 1.28 (0.93–1.75) | 0.13 | 0.54 |
| Genotyping method | |||||||||||
| RFLP | 19 | 3756/5802 | 1.07 (0.97–1.18) | 0.13 | 0.20 | 1.08 (0.97–1.21) | 0.16 | 0.18 | 1.08 (0.83–1.40) | 0.57 | 0.59 |
| Others | 15 | 11612/18157 | 1.01 (0.95–1.07) | 0.12 | 0.77 | 1.00 (0.94–1.07) | 0.94 | 0.15 | 1.03 (0.86–1.23) | 0.76 | 0.09 |